{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T22:53:36Z","timestamp":1791672816340,"version":"4.3.4"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T00:00:00Z","timestamp":1552521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s40265-019-01090-4","type":"journal-article","created":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T05:46:20Z","timestamp":1552542380000},"page":"543-554","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":179,"title":["Migalastat: A Review in Fabry Disease"],"prefix":"10.1007","volume":"79","author":[{"given":"Emma H.","family":"McCafferty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley J.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,14]]},"reference":[{"issue":"4","key":"1090_CR1","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","volume":"123","author":"A Ortiz","year":"2018","unstructured":"Ortiz A, Germain DP, Desnick RJ, et al. Fabry disease revisited: management and treatment recommendations for adult patients. Mol Genet Metab. 2018;123(4):416\u201327.","journal-title":"Mol Genet Metab."},{"key":"1090_CR2","unstructured":"Amicus Therapeutics. Galafold\u2122 (migalastat) capsules, for oral use: US prescribing information. 2018. \n                    https:\/\/www.fda.gov\/\n                    \n                  . Accessed 18 Oct 2018."},{"key":"1090_CR3","unstructured":"European Medicines Agency. Migalastat (Galafold): EU summary of product characteristics. 2018. \n                    https:\/\/www.ema.europa.eu\/\n                    \n                  . Accessed 18 Oct 2018."},{"issue":"21","key":"1090_CR4","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","volume":"276","author":"RO Brady","year":"1967","unstructured":"Brady RO, Gal AE, Bradley RM, et al. Enzymatic defect in Fabry\u2019s disease. Ceramidetrihexosidase deficiency. N Engl J Med. 1967;276(21):1163\u20137.","journal-title":"N Engl J Med."},{"key":"1090_CR5","unstructured":"National Institute for Health and Care Excellence. Migalastat for treating Fabry disease. 2017. \n                    https:\/\/www.nice.org.uk\/guidance\/hst4\n                    \n                  . Accessed 26 Oct 2018."},{"issue":"5","key":"1090_CR6","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1681\/ASN.2016090964","volume":"28","author":"M Arends","year":"2017","unstructured":"Arends M, Wanner C, Hughes D, et al. Characterization of classical and nonclassical Fabry disease: a multicenter study. J Am Soc Nephrol. 2017;28(5):1631\u201341.","journal-title":"J Am Soc Nephrol."},{"issue":"7","key":"1090_CR7","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1023\/A:1012993305223","volume":"24","author":"C Whybra","year":"2001","unstructured":"Whybra C, Kampmann C, Willers I, et al. Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes. J Inherit Metab Dis. 2001;24(7):715\u201324.","journal-title":"J Inherit Metab Dis."},{"issue":"9","key":"1090_CR8","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/S0735-1097(02)02380-X","volume":"40","author":"C Kampmann","year":"2002","unstructured":"Kampmann C, Baehner F, Whybra C, et al. Cardiac manifestations of Anderson\u2013Fabry disease in heterozygous females. J Am Coll Cardiol. 2002;40(9):1668\u201374.","journal-title":"J Am Coll Cardiol."},{"key":"1090_CR9","doi-asserted-by":"publisher","first-page":"336","DOI":"10.3389\/fneur.2018.00336","volume":"9","author":"L Hauth","year":"2018","unstructured":"Hauth L, Kerstens J, Yperzeele L, et al. Galactosidase alpha p.A143T variant of Fabry disease may result in a phenotype with multifocal microvascular cerebral involvement at a young age. Front Neurol. 2018;9:336.","journal-title":"Front Neurol."},{"key":"1090_CR10","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1750-1172-5-30","volume":"5","author":"DP Germain","year":"2010","unstructured":"Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30.","journal-title":"Orphanet J Rare Dis."},{"issue":"4","key":"1090_CR11","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1093\/glycob\/cwg034","volume":"13","author":"K Lee","year":"2003","unstructured":"Lee K, Jin X, Zhang K, et al. A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology. 2003;13(4):305\u201313.","journal-title":"Glycobiology."},{"issue":"11","key":"1090_CR12","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1097\/GIM.0b013e3181f13b75","volume":"12","author":"O Lidove","year":"2010","unstructured":"Lidove O, West ML, Pintos-Morell G, et al. Effects of enzyme replacement therapy in Fabry disease\u2014a comprehensive review of the medical literature. Genet Med. 2010;12(11):668\u201379.","journal-title":"Genet Med."},{"issue":"2","key":"1090_CR13","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.kint.2016.10.004","volume":"91","author":"R Schiffmann","year":"2017","unstructured":"Schiffmann R, Hughes DA, Linthorst GE, et al. Screening, diagnosis, and management of patients with Fabry disease: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) controversies conference. Kidney Int. 2017;91(2):284\u201393.","journal-title":"Kidney Int."},{"issue":"7","key":"1090_CR14","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1038\/mt.2015.62","volume":"23","author":"G Parenti","year":"2015","unstructured":"Parenti G, Andria G, Valenzano KJ. Pharmacological chaperone therapy: preclinical development, clinical translation, and prospects for the treatment of lysosomal storage disorders. Mol Ther. 2015;23(7):1138\u201348.","journal-title":"Mol Ther."},{"issue":"3","key":"1090_CR15","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s10545-009-1077-0","volume":"32","author":"ER Benjamin","year":"2009","unstructured":"Benjamin ER, Flanagan JJ, Schilling A, et al. The pharmacological chaperone 1-deoxygalactonojirimycin increases alpha-galactosidase A levels in Fabry patient cell lines. J Inherit Metab Dis. 2009;32(3):424\u201340.","journal-title":"J Inherit Metab Dis."},{"issue":"1","key":"1090_CR16","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/4801","volume":"5","author":"J-Q Fan","year":"1999","unstructured":"Fan J-Q, Ishii S, Asano N, et al. Accelerated transport and maturation of lysosomal \u03b1-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat Med. 1999;5(1):112\u20135.","journal-title":"Nat Med."},{"issue":"1","key":"1090_CR17","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1096\/fj.04-2375com","volume":"19","author":"GH Yam","year":"2005","unstructured":"Yam GH, Zuber C, Roth J. A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder. Faseb J. 2005;19(1):12\u20138.","journal-title":"Faseb J."},{"issue":"13","key":"1090_CR18","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1046\/j.1432-1327.2000.01457.x","volume":"267","author":"N Asano","year":"2000","unstructured":"Asano N, Ishii S, Kizu H, et al. In vitro inhibition and intracellular enhancement of lysosomal alpha-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives. Eur J Biochem. 2000;267(13):4179\u201386.","journal-title":"Eur J Biochem."},{"issue":"4","key":"1090_CR19","doi-asserted-by":"publisher","first-page":"C1076","DOI":"10.1152\/ajpcell.00426.2005","volume":"290","author":"GH Yam","year":"2006","unstructured":"Yam GH, Bosshard N, Zuber C, et al. Pharmacological chaperone corrects lysosomal storage in Fabry disease caused by trafficking-incompetent variants. Am J Physiol Cell Physiol. 2006;290(4):C1076\u201382.","journal-title":"Am J Physiol Cell Physiol."},{"issue":"1","key":"1090_CR20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/mt.2009.220","volume":"18","author":"R Khanna","year":"2010","unstructured":"Khanna R, Soska R, Lun Y, et al. The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease. Mol Ther. 2010;18(1):23\u201333.","journal-title":"Mol Ther."},{"issue":"3","key":"1090_CR21","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1124\/jpet.108.149054","volume":"328","author":"S Ishii","year":"2009","unstructured":"Ishii S, Chang H-H, Yoshioka H, et al. Preclinical efficacy and safety of 1-deoxygalactonojirimycin in mice for Fabry disease. J Pharmacol Exp Ther. 2009;328(3):723\u201331.","journal-title":"J Pharmacol Exp Ther."},{"issue":"3","key":"1090_CR22","doi-asserted-by":"publisher","first-page":"e57631","DOI":"10.1371\/journal.pone.0057631","volume":"8","author":"B Young-Gqamana","year":"2013","unstructured":"Young-Gqamana B, Brignol N, Chang HH, et al. Migalastat HCl reduces globotriaosylsphingosine (lyso-Gb3) in Fabry transgenic mice and in the plasma of Fabry patients. PLoS ONE. 2013;8(3):e57631.","journal-title":"PLoS ONE."},{"issue":"2","key":"1090_CR23","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/cpdd.1","volume":"2","author":"FK Johnson","year":"2013","unstructured":"Johnson FK, Mudd PN Jr, Bragat A, et al. Pharmacokinetics and safety of migalastat HCl and effects on agalsidase activity in healthy volunteers. Clin Pharmacol Drug Dev. 2013;2(2):120\u201332.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"91","key":"1090_CR24","first-page":"1","volume":"7","author":"DP Germain","year":"2012","unstructured":"Germain DP, Giugliani R, Hughes DA, et al. Safety and pharmacodynamic effects of a pharmacological chaperone on alpha-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies. Orphanet J Rare Dis. 2012;7(91):1\u201311.","journal-title":"Orphanet J Rare Dis."},{"issue":"1","key":"1090_CR25","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ymgme.2013.01.009","volume":"109","author":"R Giugliani","year":"2013","unstructured":"Giugliani R, Waldek S, Germain DP, et al. A phase 2 study of migalastat hydrochloride in females with Fabry disease: selection of population, safety and pharmacodynamic effects. Mol Genet Metab. 2013;109(1):86\u201392.","journal-title":"Mol Genet Metab."},{"issue":"37","key":"1090_CR26","doi-asserted-by":"publisher","first-page":"61415","DOI":"10.18632\/oncotarget.18250","volume":"8","author":"A Tuttolomondo","year":"2017","unstructured":"Tuttolomondo A, Simonetta I, Duro G, et al. Inter-familial and intra-familial phenotypic variability in three Sicilian families with Anderson\u2013Fabry disease. OncoTarget. 2017;8(37):61415\u201324.","journal-title":"OncoTarget."},{"issue":"4","key":"1090_CR27","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","volume":"54","author":"DA Hughes","year":"2017","unstructured":"Hughes DA, Nicholls K, Shankar SP, et al. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. J Med Genet. 2017;54(4):288\u201396.","journal-title":"J Med Genet."},{"issue":"4","key":"1090_CR28","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/gim.2016.122","volume":"19","author":"ER Benjamin","year":"2017","unstructured":"Benjamin ER, Della Valle MC, Wu X, et al. The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat. Genet Med. 2017;19(4):430\u20138.","journal-title":"Genet Med."},{"issue":"6","key":"1090_CR29","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1510198","volume":"375","author":"DP Germain","year":"2016","unstructured":"Germain DP, Hughes DA, Nicholls K, et al. Treatment of Fabry\u2019s disease with the pharmacologic chaperone migalastat. N Engl J Med. 2016;375(6):545\u201355.","journal-title":"N Engl J Med."},{"issue":"8","key":"1090_CR30","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/humu.21530","volume":"32","author":"X Wu","year":"2011","unstructured":"Wu X, Katz E, Della Valle MC, et al. A pharmacogenetic approach to identify mutant forms of alpha-galactosidase A that respond to a pharmacological chaperone for Fabry disease. Hum Mutat. 2011;32(8):965\u201377.","journal-title":"Hum Mutat."},{"issue":"4","key":"1090_CR31","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/cpdd.149","volume":"4","author":"FK Johnson","year":"2015","unstructured":"Johnson FK, Mudd PN Jr, DiMino T, et al. An open-label study to determine the pharmacokinetics and safety of migalastat HCl in subjects with impaired renal function and healthy subjects with normal renal function. Clin Pharmacol Drug Dev. 2015;4(4):256\u201361.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"1","key":"1090_CR32","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3109\/21556660.2013.827117","volume":"2","author":"H Ino","year":"2013","unstructured":"Ino H, Takahashi N, Terao T, et al. Pharmacokinetics, safety, and tolerability following single-dose migalastat hydrochloride (GR181413A\/AT1001) in healthy male Japanese subjects. J Drug Assess. 2013;2(1):87\u201393.","journal-title":"J Drug Assess."},{"issue":"Suppl. 1","key":"1090_CR33","first-page":"3","volume":"6","author":"FK Johnson","year":"2017","unstructured":"Johnson FK, Valenzano KJ, Castelli JP, et al. Pharmacokinetic simulation of a 150\u00a0mg QOD dose regimen for the pharmacological chaperone migalastat HCl in Fabry disease [abstract no. 001]. Clin Pharmacol Drug Dev. 2017;6(Suppl. 1):3.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"3","key":"1090_CR34","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/cpdd.147","volume":"4","author":"FK Johnson","year":"2015","unstructured":"Johnson FK, Mudd PN Jr, Janmohamed SG. Relative bioavailability and the effect of meal type and timing on the pharmacokinetics of migalastat in healthy volunteers. Clin Pharmacol Drug Dev. 2015;4(3):193\u2013202.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"Suppl. 1","key":"1090_CR35","first-page":"18","volume":"2","author":"PN Mudd","year":"2013","unstructured":"Mudd PN, Johnson FK, Churchill A. A phase 1 study to investigate the absorption, metabolism and excretion of [14C] migalastat hydrochloride following a single oral administration in healthy volunteers [abstract no. 1699358]. Clin Pharmacol Drug Dev. 2013;2(Suppl. 1):18\u20139.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"1090_CR36","unstructured":"Amicus Therapeutics. NDA multi-disciplinary review and evaluation: Galafold (migalastat). 2017. \n                    https:\/\/www.fda.gov\/\n                    \n                  . Accessed 6 Nov 2018."},{"issue":"11","key":"1090_CR37","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1136\/jmedgenet-2017-104826","volume":"54","author":"M Mauer","year":"2017","unstructured":"Mauer M, Sokolovskiy A, Barth JA, et al. Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable GLA mutations following 6\u00a0months of migalastat treatment. J Med Genet. 2017;54(11):781\u20136.","journal-title":"J Med Genet."},{"issue":"68","key":"1090_CR38","first-page":"1","volume":"13","author":"R Schiffmann","year":"2018","unstructured":"Schiffmann R, Bichet DG, Jovanovic A, et al. Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trial. Orphanet J Rare Dis. 2018;13(68):1\u20137.","journal-title":"Orphanet J Rare Dis."},{"key":"1090_CR39","unstructured":"The Renal Association. CKD stages G1 or G2. 2018. \n                    https:\/\/renal.org\/information-resources\/the-uk-eckd-guide\/stages-1-2-ckd\/\n                    \n                  . Accessed 19 Dec 2018."},{"key":"1090_CR40","unstructured":"National Kidney Foundation. Glomerular filtration rate (GFR). 2017. \n                    https:\/\/www.kidney.org\/atoz\/content\/gfr\n                    \n                  . Accessed 19 Dec 2018."},{"issue":"Suppl. 1","key":"1090_CR41","doi-asserted-by":"publisher","first-page":"i346","DOI":"10.1093\/ndt\/gfy104.SP002","volume":"33","author":"R Torra","year":"2018","unstructured":"Torra R, Germain D, Bichet D, et al. Clinical outcomes with migalastat in patients with Fabry disease based on degree of renal impairment: results from phase 3 trials [abstract no. SP002 and poster]. Nephrol Dial Transplant. 2018;33(Suppl. 1):i346.","journal-title":"Nephrol Dial Transplant."},{"issue":"1\u20132","key":"1090_CR42","first-page":"S52","volume":"120","author":"DP Germain","year":"2017","unstructured":"Germain DP, Giugliani R, Bichet DG, et al. Efficacy of migalastat in a cohort of male patients with the classic Fabry phenotype in the FACETS phase 3 study [abstract no. 102]. Mol Genet Metab. 2017;120(1\u20132):S52.","journal-title":"Mol Genet Metab."},{"issue":"Suppl. 1","key":"1090_CR43","first-page":"i346","volume":"33","author":"R Schiffmann","year":"2018","unstructured":"Schiffmann R, Bichet D, Germain D, et al. Effects of long-term migalastat treatment on renal function by baseline proteinuria in patients (PTS) with Fabry disease [abstract no. SP004 and poster]. Nephrol Dial Transplant. 2018;33(Suppl. 1):i346\u20137.","journal-title":"Nephrol Dial Transplant."},{"key":"1090_CR44","first-page":"1","volume":"5","author":"A Jovanovic","year":"2017","unstructured":"Jovanovic A, Schiffmann R, Nicholls K, et al. Improvements in cardiac mass with long-term migalastat treatment in patients with Fabry disease: results from phase 3 trials [abstract no. LBN 02]. J Inborn Errors Metab Screen. 2017;5:1\u20132.","journal-title":"J Inborn Errors Metab Screen"},{"issue":"Suppl. 1","key":"1090_CR45","first-page":"460","volume":"39","author":"J Muentze","year":"2018","unstructured":"Muentze J, Gensler D, Salinger T, et al. Treatment of cardiac manifestations in Fabry disease with the oral drug migalastat: first 12\u00a0months results from a cohort of amenable all-comers [abstract no. 2355]. Eur Heart J. 2018;39(Suppl. 1):460.","journal-title":"Eur Heart J."},{"key":"1090_CR46","unstructured":"Health Canada. Galafold\u2122 (migalastat) capsules: Canadian product monograph. 2017. \n                    https:\/\/pdf.hres.ca\/dpd_pm\/00041104.PDF\n                    \n                  . Accessed 16 Jan 2019."},{"key":"1090_CR47","unstructured":"Japanese Pharmaceuticals and Medical Devices Agency. Galafold capsule 123\u00a0mg: Japanese prescribing information. 2018. \n                    http:\/\/www.info.pmda.go.jp\/go\/pack\/3999045M1028_1_01\/\n                    \n                  . Accessed 18 Oct 2018."},{"key":"1090_CR48","unstructured":"Therapeutic Goods Administration. Galafold\u00ae (migalastat): Australian product information. 2018. \n                    https:\/\/www.tga.gov.au\/sites\/default\/files\/auspar-migalastat-180830-pi.pdf\n                    \n                  . Accessed 16 Jan 2019."},{"issue":"11","key":"1090_CR49","doi-asserted-by":"publisher","first-page":"e112188","DOI":"10.1371\/journal.pone.0112188","volume":"9","author":"M Mauer","year":"2014","unstructured":"Mauer M, Glynn E, Svarstad E, et al. Mosaicism of podocyte involvement is related to podocyte injury in females with Fabry disease. PLoS ONE. 2014;9(11):e112188.","journal-title":"PLoS ONE."},{"issue":"1","key":"1090_CR50","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13023-016-0441-z","volume":"11","author":"M Lenders","year":"2016","unstructured":"Lenders M, Weidemann F, Kurschat C, et al. Alpha-galactosidase A p.A143T, a non-Fabry disease-causing variant. Orphanet J Rare Dis. 2016;11(1):54.","journal-title":"Orphanet J Rare Dis."},{"key":"1090_CR51","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/8904_2012_167","volume":"8","author":"W Terryn","year":"2013","unstructured":"Terryn W, Vanholder R, Hemelsoet D, et al. Questioning the pathogenic role of the GLA p.Ala143Thr \u201cmutation\u201d in Fabry disease: implications for screening studies and ERT. JIMD Rep. 2013;8:101\u20138.","journal-title":"JIMD Rep."},{"issue":"4","key":"1090_CR52","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/mgg3.389","volume":"6","author":"DP Germain","year":"2018","unstructured":"Germain DP, Brand E, Burlina A, et al. Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: a multicenter Fabry Registry study. Mol Genet Genomic Med. 2018;6(4):492\u2013503.","journal-title":"Mol Genet Genomic Med."},{"issue":"5","key":"1090_CR53","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/emmm.200900036","volume":"1","author":"G Parenti","year":"2009","unstructured":"Parenti G. Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics. EMBO Mol Med. 2009;1(5):268\u201379.","journal-title":"EMBO Mol Med."},{"key":"1090_CR54","unstructured":"European Medicines Agency. Agalsidase beta (Fabrazyme): EU summary of product characteristics. 2018. \n                    https:\/\/www.ema.europa.eu\/\n                    \n                  . Accessed 26 Oct 2018."},{"key":"1090_CR55","unstructured":"European Medicines Agency. Agalsidase alfa (Replagal): EU summary of product characteristics. 2018. \n                    https:\/\/www.ema.europa.eu\/\n                    \n                  . Accessed 26 Oct 2018."},{"key":"1090_CR56","doi-asserted-by":"publisher","first-page":"448","DOI":"10.3389\/fphar.2017.00448","volume":"8","author":"FE Mohamed","year":"2017","unstructured":"Mohamed FE, Al-Gazali L, Al-Jasmi F, et al. Pharmaceutical chaperones and proteostasis regulators in the therapy of lysosomal storage disorders: current perspective and future promises. Front Pharmacol. 2017;8:448.","journal-title":"Front Pharmacol."},{"key":"1090_CR57","unstructured":"Therapeutic Goods Administration. Australian public assessment report for migalastat. 2018. \n                    https:\/\/www.tga.gov.au\/sites\/default\/files\/auspar-migalastat-180830.pdf\n                    \n                  . Accessed 16 Jan 2019."},{"key":"1090_CR58","unstructured":"Sirrs S, Bichet DG, Iwanochko RM, et al. 2017 Canadian Fabry disease guidelines. 2017. \n                    http:\/\/www.garrod.ca\/wp-content\/uploads\/Canadian-FD-Treatment-Guidelines-2017.pdf\n                    \n                  . Accessed 16 Jan 2019."},{"key":"1090_CR59","unstructured":"US National Institutes of Health. ClinicalTrials.gov identifier NCT03683966. 2018. \n                    https:\/\/clinicaltrials.gov\/\n                    \n                  . Accessed 16 Jan 2019."},{"key":"1090_CR60","unstructured":"BlueCross BlueShield of Arizona. Galafold\u2122 (migalastat) oral capsule: pharmacy coverage guidelines. 2018. \n                    https:\/\/www.azblue.com\/~\/media\/azblue\/files\/pharmacy-forms-mastery-directory\/qualified-health-plans\/pharmacy-coverage-guidelines-and-precertification-forms\/galafold.pdf\n                    \n                  . Accessed 17 Jan 2019."},{"key":"1090_CR61","unstructured":"Amicus Therapeutics. Galafold\u2122 (migalastat) capsules: NDA approval letter. 2018. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2018\/208623Orig1s000ltr.pdf\n                    \n                  . Accessed 18 Dec 2018."}],"updated-by":[{"DOI":"10.1007\/s40265-019-01166-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T00:00:00Z","timestamp":1562716800000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01090-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-019-01090-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01090-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T20:28:09Z","timestamp":1584044889000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-019-01090-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,14]]},"references-count":61,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["1090"],"URL":"https:\/\/doi.org\/10.1007\/s40265-019-01090-4","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,14]]},"assertion":[{"value":"14 March 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2019","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The article Migalastat: A Review in Fabry Disease, written by Emma H. McCafferty, Lesley J. Scott, was originally published Online First without open access. After publication in volume 79, issue 5, pages 543\u2013554 [funder] requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by [funder]. The article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/), which permits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Emma McCafferty and Lesley Scott are salaried employees of Adis\/Springer, are responsible for the article content and declare no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}